

REMARKS

With entry of this amendment, the status of the claims is as follows:

Original:	1, 2 and 10
Currently amended:	3-9 and 13-18
Previously presented:	None
Canceled:	11 and 12
Withdrawn:	None
New:	19

With entry of this amendment, claims 1-10 and 13-19 are pending.

The specification has been amended to contain a reference to the United Kingdom application for which a benefit of priority is being claimed.

The multiple dependencies have been removed from claims 3-7, 13 and 15-18.

Use claims 11 and 12 have been canceled.

The unnecessary references back to definitions in Claim 1 have been removed from claims 8 and 9.

The reference to "involving" in claims 15 and 16 has been replaced with "comprises".

The "such as" and "preferably" language in claims 14, 15 and 17 has been removed.

The reference in claim 15 to a pharmaceutical composition has been removed and made the subject of new claim 19.

No new matter has been introduced by any of the changes to the specification and claims.

Respectfully submitted,

Date: April 7, 2006

By: Kenneth R. Walton  
Kenneth R. Walton, Reg. No. 32,951  
Attorney for Applicants  
MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
Tel.: (732) 594-3462